The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so conclusive that the company not only halted the study for efficacy ...

In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Merck (MRK) announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR compared to placebo in adults with ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

WINREVAIR is currently approved in more than 40 countries based on the results from the STELLAR trial. Merck announced in January 2025 that the Phase 3 HYPERION study evaluating WINREVAIR when ...

Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.

Merck (NYSE:MRK) recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual ...